(833) 317-6278 
Indian drugmaker Aurobindo's Eugia manufacturing arm suffered another blow from the FDA after the U.S. regulatory agency issued a warning letter in the wake of previous inspections.
Joseph Keenan
Geo Focus
Coverage Attributes:
Beta
Press Release:
37
%
Government Announcement:
25
%
Private Sector Announcements:
19
%
Cites Data:
6
%
Legal Policy Regulation:
6
%
Themes Covered:
Not enough data
Pitching Insights
Joseph Keenan's coverage is heavily focused on healthcare and pharmaceuticals, specifically around industry announcements such as collaborations, partnerships, and government classifications. He tends to cover news related to drug manufacturing, clinical trials, FDA activities, and other significant developments within the pharmaceutical industry.
Based on his coverage attributes and topics covered, Joseph would likely be interested in receiving pitches related to new drug approvals or rejections by the FDA, major collaborations or partnerships within the pharmaceutical sector (especially those involving prominent companies), as well as updates on clinical trials and drug recalls.
Pitches with a focus on government actions impacting the pharmaceutical industry could also resonate with him given his extensive coverage of press releases and government announcements. It's important for sources reaching out to Joseph to provide clear data-driven insights or access to exclusive information related to these areas of focus.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Journalists With Similar Coverage:
Based on similarity of content.
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
